After Cowen & Co. and J.P. Morgan gave Dynavax (NASDAQ: DVAX) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Elemer Piros reiterated a Buy rating on Dynavax today and set a price target of $27. The company’s shares opened today at $16.35.
Piros observed:
“Dynavax’s approved product, HEPLISAV-B, is a TLR9 agonist (1018 ISS) combined with recombinant Hepatitis surface Antigen (rHBsAg) used to vaccinate adults for the prophylaxis of HBV infection. When compared with existing vaccines, HEPLISAV-B has demonstrated higher protection in general patient groups and in high-risk patient populations, with a significantly more convenient dosing profile. HEPLISAV-B was approved on November 9, 2017.”
According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.3% and a 49.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Dynavax has an analyst consensus of Strong Buy, with a price target consensus of $29.80.
See today’s analyst top recommended stocks >>
Based on Dynavax’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $38.96 million. In comparison, last year the company had a GAAP net loss of $25.29 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.
Read More on DVAX:
